<DOC>
	<DOCNO>NCT01337440</DOCNO>
	<brief_summary>1 . Objectives 1 . To test whether Ursodeoxycholic Acid ( UDCA ) increase Glucagon-like peptide-1 ( GLP-1 ) response nutrient improve glycemic control people type 2 diabetes . 2 . To test whether sitagliptin enhances UDCA-induced beneficial effect GLP-1 level glycemic control . 3 . To test safety combination therapy sitagliptin UDCA people type 2 diabetes . 2 . Clinical hypothesis . 1 . UDCA increase GLP-1 response nutrient via provoke bile acid excretion liver intestine/colon . 2 . UDCA improve glycemic control people type 2 diabetes . 3 . Sitagliptin enhance UDCA-induced response GLP-1 nutrient . 4 . Sitagliptin additive beneficial effect UDCA glycemic control people type 2 diabetes . 5 . Combination therapy sitagliptin UDCA safe well-tolerated people type 2 diabetes . 6 . The combination therapy may loose weight unique mechanisms agent ; GLP-1 inhibit appetite acting CNS gastrointestinal motility , whereas UDCA-enhanced circulate primary bile acid increase energy expenditure pathway involve G protein-coupled bile acid receptor 1 ( Gpbar1 , M-Bar , TGR-5 ) subsequent activation type 2 iodothyronine deiodinase ( D2 ) brown adipose muscle tissue , report previously .</brief_summary>
	<brief_title>Efficacy Safety Ursodeoxycholic Acid ( UDCA ) Added DPP-4 Inhibitor People With Type 2 Diabetes Chronic Liver Diseases</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>1 . Type 2 diabetes 2 . HbA1c &gt; =6.5 % 8 week prior study 3 . Treated none single oral hypoglycemic agent ( OHA : sulfonyl urea , biguanides , thiazolidinediones ) 12 week prior study 1 . NonType 2 diabetes 2 . Medical history and/or complication diabetic ketoacidosis 3 . Medical history and/or complication severe hypoglycemia 4 . Insulin treatment within 16 week prior study 5 . Treatment alphaglucosidase inhibitor sitagliptin within 12 week prior study 6 . Treatment glucocorticoid 7 . Unstable glycemic control 8 . Hypersensitivity contraindication sitagliptin voglibose 9 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; =2.5 time institutional upper normal limit 10 . Uncontrolled hypertension ( systolic blood pressure &gt; 160mmHg diastolic blood pressure &gt; 100mmHg ) 11 . Severe health problem suitable study 12 . Pregnant lactate woman 13 . Hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Ursodeoxycholic Acid</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>bile acid</keyword>
	<keyword>GLP-1</keyword>
</DOC>